Everything below concerns Aggregation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control of reconstituted peptides combines visual inspection with instrumental analysis. A clear solution does not prove correct identity or purity, and a cloudy solution does not always indicate failure. Reverse-phase high-performance liquid chromatography can separate the peptide from related impurities, while mass spectrometry confirms molecular mass and detects modifications. pH measurement and osmolality checks provide additional information about the solution environment, and documentation of lot number, solvent, and storage history supports traceability.
After a peptide is reconstituted, handling practices affect its chemical and physical stability over time. Aqueous solutions can support microbial growth unless they are prepared with aseptic technique or contain preservatives. Container material matters because peptides can adsorb to glass or plastic surfaces, reducing the amount available in solution. Repeated transfers increase exposure to air and potential contaminants, and temperature fluctuations can accelerate degradation. These factors are separate from the peptide's intrinsic sequence-based stability.
Storage conditions for reconstituted peptides are product-specific. Cool temperatures slow many degradation pathways, but freezing can concentrate solutes and promote aggregation. Light exposure can oxidize susceptible residues such as methionine, cysteine, or tryptophan. Oxygen in headspace can contribute to oxidation, while acidic or basic pH can drive hydrolysis and deamidation. The best storage condition for a given sequence is often determined empirically because general rules do not capture all sequence-specific effects.
The choice of solvent is guided by peptide properties and the intended downstream use. Water alone can dissolve many hydrophilic peptides, while hydrophobic sequences may require a small amount of an organic solvent or a buffered solution. Some peptides carry net charges that affect solubility across pH values. The pH of the final solution can influence stability and aggregation. In research settings, the solvent is selected to match the assay or analytical method rather than for any therapeutic purpose.
During reconstitution, liquid is directed toward the wall of the vial rather than forcefully onto the powder. Gentle swirling or inversion mixes the contents without creating excessive foam or shear. Foaming can denature some peptides and can make volume measurement difficult. Complete dissolution is often confirmed by visual inspection against a light source. Particles, cloudiness, or undissolved material may indicate incomplete mixing, aggregation, or a solubility limitation that requires further investigation.
Peptide reconstitution is the addition of a liquid to a dried peptide preparation so that the peptide dissolves and forms a solution. Many research peptides are supplied as lyophilized powders, a form produced by freezing and then removing solvent under vacuum. The dried material often appears as a cake or fluffy powder. Dissolution depends on the peptide's sequence, charge, and hydrophobicity. Not all peptides dissolve equally in the same liquid.
| Property | Value | Notes |
|---|---|---|
| Appearance of reconstituted solution | Clear to slightly opalescent | Turbidity or visible particles may indicate aggregation or incomplete dissolution. |
| pH range | Peptide-dependent | Buffer choice should be based on stability data when available. |
| Typical storage temperature for lyophilized powder | −20 °C or below | Desiccant and a sealed container reduce moisture uptake. |
| Typical storage temperature for reconstituted solution | 2–8 °C | Freezing may be used for longer intervals, but freeze-thaw cycles can promote aggregation. |
| Identity confirmation method | Mass spectrometry | Confirms molecular mass and detects chemical modifications. |
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
After reconstitution, peptide solutions are generally less stable than lyophilized powders, and hydrolysis, oxidation, deamidation, and aggregation can occur in solution. Stability depends on peptide sequence, concentration, pH, buffer composition, temperature, light exposure, and dissolved oxygen. Many research protocols store reconstituted solutions at 4 °C for short periods or at -20 °C or -80 °C for longer periods. Repeated freeze-thaw cycles can promote aggregation and loss of activity. The optimal storage condition is peptide-specific and often determined empirically rather than predicted from sequence alone.
Quality control after reconstitution often includes visual inspection for particulates, pH measurement, and concentration determination by ultraviolet absorbance at 280 nm when aromatic residues are present. Reverse-phase high-performance liquid chromatography can assess purity and reveal degradation peaks. Mass spectrometry confirms molecular identity and detects modifications such as oxidation or truncation. Size-exclusion chromatography can quantify aggregates and oligomers. These methods are established for many peptides but may require optimization for hydrophobic or chemically modified sequences.
Microbial contamination is a concern for aqueous peptide solutions, especially those without preservatives. Bacteriostatic water contains an antimicrobial preservative and is used in some laboratory settings, while sterile water lacks preservatives. Filtration through a sterile filter can reduce particulates and microbes, but some peptides adsorb to filter membranes. The effect of preservatives on peptide stability is peptide-dependent and not fully predictable. Documentation of lot number, solvent, date, and storage conditions supports traceability and reproducibility.
Lyophilized peptides are supplied as dry powders or porous cakes that remain stable during shipment and short-term storage. Reconstitution is the laboratory step of adding a suitable solvent so the solid dissolves into a liquid stock. The dried state limits hydrolysis and microbial growth, but it does not remove all residual water or salts. Sequence, counterion, and manufacturing method influence how quickly and completely a peptide enters solution. Researchers treat reconstitution as a practical starting point for later dilution, analysis, or assay work.
Solvent choice depends on peptide polarity and intended use. Many peptides dissolve in water or buffered aqueous solutions, while hydrophobic sequences may need a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before aqueous dilution. The solvent should match the downstream analytical method and not interfere with detection. Gentle mixing or brief sonication can help, but vigorous agitation may promote foaming or aggregation. Complete dissolution is judged by a clear liquid free of visible particles, though some turbidity can persist.
At typical clinical doses used for Parkinson's disease, selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), increasing brain levels of dopamine. At higher doses, it loses its specificity for MAO-B and also inhibits monoamine oxidase A (MAO-A), which increases serotonin and norepinephrine levels in the brain as well. In addition to its MAOI activity, selegiline is a catecholaminergic activity enhancer (CAE) and enhances the impulse-mediated release of norepinephrine and dopamine in the brain. This action may be mediated by TAAR1 agonism. After administration, selegiline partially metabolizes into levomethamphetamine and levoamphetamine, which act as norepinephrine releasing agents (NRAs) and may contribute to its therapeutic and adverse effects as well. The levels of these metabolites are much lower with the ODT and transdermal patch forms of selegiline. Chemically, selegiline is a substituted phenethylamine and amphetamine, a derivative of methamphetamine, and the purified levorotatory enantiomer of deprenyl (the racemic mixture of selegiline and D-deprenyl). Deprenyl was discovered and studied as an antidepressant in the early 1960s by Zoltan Ecseri, József Knoll, and other colleagues at Chinoin Pharmaceutical Company in Hungary. Subsequently, selegiline was purified from deprenyl and was studied and developed itself. Selegiline was first introduced for medical use, to treat Parkinson's disease, in Hungary in 1977. It was subsequently approved in the United Kingdom in 1982 and in the United States in 1989.
The Chinese government has introduced a number of "fat farms" where obese children go for reinforced exercise and has passed a law which requires students to exercise or play sports for an hour a day at school (see Obesity in China). In a structured setting with a trained therapist, these interventions produce an average weight loss of up to 8 kg in 6 months to 1 year, and 67% of people who lost greater than 10% of their body mass maintained or continued to lose weight one year later. There is a gradual weight regain after the first year of about 1 to 2 kg per year, but on the long-term this still results in weight loss. Risk factors for cardiovascular disease and for diabetes are reduced for several years after taking part in a weight management programme, even if people regained weight. Attending group meetings for weight reduction programmes rather than receiving one-on-one support may increase the likelihood that obese people will lose weight. Those who participated in groups had more treatment time and were more likely to lose enough weight to improve their health. Study authors suggested that one explanation for the difference is that group participants spent more time with the clinician (or whoever delivered the programme) than those receiving one-on-one support. Comprehensive diet programs, providing counseling, targets for calorie intake and exercise, may be more efficient than dieting without guidance ("self-help"), although the evidence is very limited.
N-Acetyl-γ-aminobutyric acid (N-acetyl-GABA), also known as N-acetyl-4-aminobutyric acid, is a metabolic intermediate in the biosynthesis of γ-aminobutyric acid (GABA) from putrescine. Other intermediates in this pathway include N-acetylputrescine and N-acetyl-γ-aminobutyraldehyde (N-acetyl-GABAL or N-acetyl-GABA aldehyde). Enzymes mediating the transformations in this pathway include putrescine acetyltransferase (PAT), monoamine oxidase B (MAO-B), aldehyde dehydrogenase (ALDH), and an unknown deacetylase enzyme. The pathway is a minor pathway in GABA synthesis compared to the main pathway in which GABA is synthesized from glutamate. However, the pathway has been found to have an important physiological role in the brain, for instance in the production of GABA in the striatum and resultant inhibition of dopaminergic neurons in this brain area.
tRNAdb (updated and completely restructured version of Spritzls tRNA compilation) Archived 2011-07-19 at the Wayback Machine tRNA surprising role in breast cancer growth Archived 2023-12-03 at the Wayback Machine tRNA link to heart disease and stroke GtRNAdb: Collection of tRNAs identified from complete genomes HGNC: Gene nomenclature of human tRNAs Molecule of the Month © RCSB Protein Data Bank: Transfer RNA Aminoacyl-tRNA Synthetases Elongation Factors Rfam entry for tRNA
Sources: en.wikipedia.org
The early or fulminant form of hemorrhagic smallpox (referred to as purpura variolosa) begins with a prodromal phase characterized by a high fever, severe headache, and abdominal pain. The skin becomes dusky and erythematous, and this is rapidly followed by the development of petechiae and bleeding in the skin, conjunctiva and mucous membranes. Death often occurs suddenly between the fifth and seventh days of illness, when only a few insignificant skin lesions are present. Some people survive a few days longer, during which time the skin detaches and fluid accumulates under it, rupturing at the slightest injury. People are usually conscious until death or shortly before. Autopsy reveals petechiae and bleeding in the spleen, kidney, serous membranes, skeletal muscles, pericardium, liver, gonads and bladder. Historically, this condition was frequently misdiagnosed, with the correct diagnosis made only at autopsy. This form is more likely to occur in pregnant women than in the general population (approximately 16% of cases in unvaccinated pregnant women were early hemorrhagic smallpox, versus roughly 1% in nonpregnant women and adult males). The case fatality rate of early hemorrhagic smallpox approaches 100%.
As of 2024, the Coffee Bean and Tea Leaf has a total of 1,232 stores in 24 countries, including Bahrain, Bangladesh, Brunei, India, Indonesia, Israel, Jordan, Kingdom of Saudi Arabia, Kuwait, Kurdistan, Malaysia, Mongolia, Myanmar, Oman, Pakistan, Panama, Paraguay, Philippines, Qatar, Singapore, South Korea, Sri Lanka, USA, and Vietnam.
== Other uses == Chart Rulership or Chart Ruler, in astrology Comfort room, another name for a public toilet Consciousness raising, in social activism Continuing resolution, a type of appropriations legislation in the US Councillor, a title for a public servant, used in Australia and New Zealand Cree language (ISO 639 alpha-2 code CR) Critical reading, a skill measured by the Scholastic Aptitude Test (SAT) Crore, a number representing 10,000,000 in the Hindu-Arabic numeral system Cr$ or ₢, symbol for Brazilian cruzeiro
Sources: en.wikipedia.org
It contained a "Mother's Room" in the tower for Eddy's personal use, furnished with rare books, silks, tapestries, rugs, a dressing gown and slippers, though she spent only one night there and it was later turned into a storage room. The archway into the room was made of Italian marble, and the word Mother was engraved on the floor. Within two years the Boston membership had exceeded the original church's capacity. By 1903 the block around the church had been purchased by Christian Scientists, and in 1906 the Mother Church Extension, accommodating 5,000 people, was completed at a cost of $2 million. This attracted the criticism that, whereas Christian Scientists spent money on a magnificent church, they maintained no hospitals, orphanages or missions in the slums. Christian Science went on to become the fastest-growing American religion in the early 20th century. The federal religious census recorded 85,717 Christian Scientists in 1906; 30 years later it was 268,915. In 1890 there were seven Christian Science churches in the United States, a figure that had risen to 1,104 by 1910. Churches began to appear in other countries too: 58 in England, 38 in Canada and 28 elsewhere by 1910.
Saline breast prosthesis filled with sterile saline solution. Silicone breast prosthesis filled with viscous silicone gel. Alternative-composition breast prosthesis filled with various fillers (soy oil, polypropylene string); now discontinued. Structured breast prosthesis constructed of nested shells, made of elastomer silicone, with saline solution filling the space between the silicone shells; now discontinued.
== Mechanisms == Follistatin is an endogenous protein that negatively regulates myostatin. Reduction of myostatin expression is one of the mechanisms for the effects of androgens in promoting muscle growth. Androgens both regulate myostatin expression directly and upregulate follistatin expression. YK-11, a selective androgen receptor modulator, is also a myostatin inhibitor. Resistance training reduces myostatin activity and increases follistatin activity. Pharmacological myostatin inhibitors can therefore be considered exercise mimetics. Creatine, a popular workout supplement, has shown some myostatin inhibitory effects in preclinical studies. Many drugs in development as myostatin inhibitors also reduce the activity of related proteins such as GDF11, activins, and bone morphogenetic proteins. While this off target activity can increase their effectiveness in promoting anabolism, it also increases the risk of adverse effects. Monoclonal antibodies have been developed that disable myostatin, including apitegromab, domagrozumab, landogrozumab, and stamulumab. Another form of myostatin inhibition is gene therapy. Another monoclonal antibody, bimagrumab, works as an antagonist of the ACVR2 and ACVR2B receptors, preventing myostatin and activin A from binding. Because activin A reduces erythropoiesis, targeting the ACVR receptors and inhibiting activin A activity can increase the risk of venous thromboembolism in patients who are not anemic.
Sources: en.wikipedia.org
There is no universal storage time because stability depends on sequence, solvent, pH, concentration, and temperature. Product-specific data or stability studies provide the most reliable guidance. In the absence of such data, short-term cold storage is common.
A buffer resists pH changes when small amounts of acid or base are introduced. For peptides, pH can influence charge, solubility, and degradation rates. The appropriate buffer depends on the peptide's stability profile and intended analytical method.
Visual clarity only shows the absence of large particles or turbidity. It does not confirm identity, purity, concentration, or biological activity. Instrumental methods such as chromatography and mass spectrometry are needed for those assessments.
Lyophilized means the material was frozen and then dried under vacuum, leaving a solid powder or cake. The process removes most of the water or solvent. The resulting peptide is typically more stable for storage than a solution.